vs
Side-by-side financial comparison of W. R. Berkley Corporation (WRB) and Zoetis (ZTS). Click either name above to swap in a different company.
W. R. Berkley Corporation is the larger business by last-quarter revenue ($3.7B vs $2.4B, roughly 1.5× Zoetis). Zoetis runs the higher net margin — 25.3% vs 14.0%, a 11.3% gap on every dollar of revenue. On growth, W. R. Berkley Corporation posted the faster year-over-year revenue change (4.0% vs 3.0%). Over the past eight quarters, W. R. Berkley Corporation's revenue compounded faster (5.5% CAGR vs 4.4%).
William Robert Berkley is the founder and current chairman of W. R. Berkley Corporation and the chairman of the New York University Board of Trustees.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
WRB vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.7B | $2.4B |
| Net Profit | $515.2M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | — | 31.9% |
| Net Margin | 14.0% | 25.3% |
| Revenue YoY | 4.0% | 3.0% |
| Net Profit YoY | — | 3.8% |
| EPS (diluted) | $1.31 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.7B | $2.4B | ||
| Q3 25 | $3.8B | $2.4B | ||
| Q2 25 | $3.7B | $2.5B | ||
| Q1 25 | $3.5B | $2.2B | ||
| Q4 24 | $3.7B | $2.3B | ||
| Q3 24 | $3.4B | $2.4B | ||
| Q2 24 | $3.3B | $2.4B |
| Q1 26 | $515.2M | — | ||
| Q4 25 | $449.5M | $603.0M | ||
| Q3 25 | $511.0M | $721.0M | ||
| Q2 25 | $401.3M | $718.0M | ||
| Q1 25 | $417.6M | $631.0M | ||
| Q4 24 | $576.1M | $581.0M | ||
| Q3 24 | $365.6M | $682.0M | ||
| Q2 24 | $371.9M | $624.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | 15.4% | 31.9% | ||
| Q3 25 | 17.2% | 37.0% | ||
| Q2 25 | 14.2% | 36.7% | ||
| Q1 25 | 15.2% | 36.5% | ||
| Q4 24 | 19.9% | 31.6% | ||
| Q3 24 | 14.0% | 36.6% | ||
| Q2 24 | 14.7% | 33.0% |
| Q1 26 | 14.0% | — | ||
| Q4 25 | 12.1% | 25.3% | ||
| Q3 25 | 13.6% | 30.0% | ||
| Q2 25 | 10.9% | 29.2% | ||
| Q1 25 | 11.8% | 28.4% | ||
| Q4 24 | 15.7% | 25.1% | ||
| Q3 24 | 10.8% | 28.6% | ||
| Q2 24 | 11.2% | 26.4% |
| Q1 26 | $1.31 | — | ||
| Q4 25 | $1.13 | $1.37 | ||
| Q3 25 | $1.28 | $1.63 | ||
| Q2 25 | $1.00 | $1.61 | ||
| Q1 25 | $1.04 | $1.41 | ||
| Q4 24 | $0.89 | $1.29 | ||
| Q3 24 | $0.91 | $1.50 | ||
| Q2 24 | $0.92 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $3.3B |
| Total Assets | $44.3B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.4B | $2.1B | ||
| Q2 25 | $2.0B | $1.4B | ||
| Q1 25 | $1.7B | $1.7B | ||
| Q4 24 | $2.0B | $2.0B | ||
| Q3 24 | $1.6B | $1.7B | ||
| Q2 24 | $1.6B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $9.7B | $3.3B | ||
| Q3 25 | $9.8B | $5.4B | ||
| Q2 25 | $9.3B | $5.0B | ||
| Q1 25 | $8.9B | $4.7B | ||
| Q4 24 | $8.4B | $4.8B | ||
| Q3 24 | $8.4B | $5.2B | ||
| Q2 24 | $7.8B | $5.0B |
| Q1 26 | $44.3B | — | ||
| Q4 25 | $44.1B | $15.5B | ||
| Q3 25 | $43.7B | $15.2B | ||
| Q2 25 | $42.7B | $14.5B | ||
| Q1 25 | $41.3B | $14.1B | ||
| Q4 24 | $40.6B | $14.2B | ||
| Q3 24 | $40.4B | $14.4B | ||
| Q2 24 | $38.9B | $14.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | — | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $995.1M | $893.0M | ||
| Q3 25 | $1.1B | $938.0M | ||
| Q2 25 | $703.8M | $486.0M | ||
| Q1 25 | $743.8M | $587.0M | ||
| Q4 24 | $810.0M | $905.0M | ||
| Q3 24 | $1.2B | $951.0M | ||
| Q2 24 | $881.3M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $732.0M | ||
| Q3 25 | — | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.21× | 1.48× | ||
| Q3 25 | 2.23× | 1.30× | ||
| Q2 25 | 1.75× | 0.68× | ||
| Q1 25 | 1.78× | 0.93× | ||
| Q4 24 | 1.41× | 1.56× | ||
| Q3 24 | 3.39× | 1.39× | ||
| Q2 24 | 2.37× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
WRB
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
